This statistic shows the death rate due to leukemia in the United States from 1999 to 2021. The maximum leukemia death rate was 7.7 per every 100,000 age-adjusted population in 1999 and 2000. The minimum rate stood at 5.8 in 2021.

Blood cancer survival rates vary widely across the globe — and the contrast between India and developed nations is both eye-opening and urgent. While countries like the U.S., UK, and Germany report survival rates of 60–75% for common blood cancers such as leukaemia, lymphoma, and myeloma, India’s figures remain significantly lower, often ranging between 30 and 40%.This gap is driven by several critical factors: late diagnosis, limited access to advanced treatments, lack of awareness, and uneven healthcare infrastructure. Yet, with timely detection and modern therapies like CAR T-cell therapy and bone marrow transplant, these numbers can improve — and lives can be saved.At bmtnext.com, BMT NEXT is working to close this survival gap by offering world-class care, cutting-edge treatment options, and personalised support for every patient. Our mission is to ensure that patients in India receive the same level of care and hope as those in the most advanced healthcare systems.It’s time to bridge the divide — and BMT NEXT is leading the way.

In 2018, Greece reported **** deaths from leukemia per 100,000 population, the highest mortality rate in Europe. Cyprus followed with **** leukemia deaths per 100,000, and then France with a rate of **** deaths per 100,000. On the other hand, there were **** deaths per 100,000 in Iceland as a result of the cancer.

This statistic shows the share of total survivals from childhood cancer in Sweden in 2018, by type. The highest share of children who survived childhood cancer were children with leukemia. Children ill with leukemia composed ** percent of the total childhood cancer survival in Sweden in 2018.

In Denmark the *** year survival rate of blood cancer was ** percent for the period 2020 to 2022. On the other hand, the *** year survival rate was just over ** percent.

Five-year relative survival ratios for prostate, gallbladder, ureter and chronic lymphocytic leukemia cancer for 3 years of cases from 1992 to 2001, by age group and sex, for Canada (excluding Quebec).

According to Cognitive Market Research, The Myelodysplastic Syndrome Treatment Market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and is projected to grow at a CAGR of XX% in the future. Europe accounted for a market share of over XX% of the global revenue with a USD XX million market size. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Myelodysplastic Syndrome Treatment Market held the highest market revenue share in 2024. Market Dynamics of the Myelodysplastic Syndrome Treatment Market

Key Drivers for The Myelodysplastic Syndrome Treatment Market

The increasing prevalence of drive the market of myeloid leukemia drives the myelodysplastic syndrome treatment market. 

The market for medications used to treat myelodysplastic syndrome (MDS) is anticipated to expand in the future due to the rising prevalence of myeloid leukemia. Treating the underlying cause of leukemia with myelodysplastic syndrome (MDS) drugs aims to enhance bone marrow function, lower the risk of complications from low blood cell counts, lessen the need for chemotherapy and transplants, and increase the survival rates of those taking these medications. According to the American Cancer Society estimates 20,380 people in the US were diagnosed during 2023, and 11,310 people died from the disease. The increasing incidence of myeloid leukemia creates the need for its treatment which drives the myelodysplastic syndrome treatment market. For instance, in January 2024, according to the estimates of the American Cancer Society, a US-based voluntary health organization, there were about 20,800 cases and 11,220 deaths of acute myeloid leukemia (AML) in adults during 2024. Source:(https://www.cancer.org/cancer/types/acute-myeloid-leukemia/about/key-statistics.html) Thus, the rising number of patients’ population with myeloid leukemia creates the need for its treatment driving the myelodysplastic syndrome treatment market.

Rising exposure to cancer treatments is expected to boost the growth of the myelodysplastic syndrome treatment market.

The myelodysplastic syndrome (MDS) medicine market is anticipated to grow due to increased exposure to cancer therapies including radiation and chemotherapy. The bone marrow's stem cells, which are responsible for producing new blood cells, are harmed by radiation therapy and chemotherapy; this harmful impact upsets the natural balance of cell formation and causes MDS. In the United States, about 25% of cancer patients receive chemotherapy each year, and around 50% receive radiation therapy. The growing number of patients adopting chemotherapy and radiation therapy causes damage to the bone marrow's stem cells resulting in the myelodysplastic syndrome, hence increasing demand for the myelodysplastic syndrome treatment market. For instance, according to ESTRO-HERO (Health Economics in Radiation Oncology) analysis by the European Society of Radiation Oncology (ESTRO), a Belgium-based organization, based on projected cancer distributions in 2025, there is an expected 16% increase in the number of radiotherapy treatment courses. Source:(https://pubmed.ncbi.nlm.nih.gov/26922487/) Therefore, rising exposure to cancer treatments, such as chemotherapy and radiation, is driving the growth of the myelodysplastic syndrome treatment market.

Restraint Factor for The Myelodysplastic Syndrome Treatment Market

The high cost of the myelodysplastic syndrome treatment restrains the growth of the myelodysplastic syndrome treatment market.

The high cost of treatment for myelodysplastic syndrome (MDS) acts as a significant barrier to the growth of the MDS treatment market. MDS is a group ...

The Acute Lymphocytic Leukemia (ALL) Treatment market is a dynamic and rapidly evolving sector in the healthcare industry, primarily focused on addressing one of the most aggressive forms of blood cancer that predominantly affects children but can also manifest in adults. The treatment landscape for ALL encompasses

N = number of cases.RS = 5-year relative survival.SE = standard errors.Diff = difference in survival between Germany and the United States.a Age-standardized.

The market offers a range of therapeutic options, includingChemotherapyBiological TherapyTargeted TherapyRadiation TherapyTargeted therapies, in particular, are gaining popularity due to their specificity and effectiveness. Recent developments include: November 2023: Pfizer announced that its new breast cancer drug, palbociclib, has been approved by the FDA for the treatment of patients with HER2-positive metastatic breast cancer. Palbociclib is a CDK4/6 inhibitor that works by blocking the growth and spread of cancer cells.Merck announced that its new breast cancer drug, pembrolizumab, has been approved by the FDA for the treatment of patients with triple-negative breast cancer (TNBC). Pembrolizumab is an immunotherapy drug that works by boosting the body's immune system to fight cancer cells. Roche announced that its new breast cancer drug, tucatinib, has been approved by the FDA for the treatment of patients with HER2-positive advanced or metastatic breast cancer. Tucatinib is a TKI that works by blocking the HER2 protein, which is involved in the growth and spread of cancer cells., October 2023: A new study published in the journal Nature Cancer finds that a combination of three drugs, including a PARP inhibitor, a CDK4/6 inhibitor, and a hormone therapy drug, is effective in shrinking tumors and prolonging survival in patients with advanced breast cancer.Another study published in the journal Cancer Discovery finds that a new AI-powered algorithm is able to predict the risk of breast cancer recurrence more accurately than traditional methods. The algorithm takes into account a variety of factors, including the patient's tumor characteristics, medical history, and lifestyle., September 2023: The American Cancer Society released its annual report on cancer statistics, which finds that the breast cancer death rate has decreased by 43% since 1990. The report also finds that the five-year survival rate for breast cancer is now 91%.The National Cancer Institute awarded a grant to a team of researchers at Harvard University to develop a new type of breast cancer vaccine. The vaccine is designed to target a specific protein that is found on the surface of breast cancer cells., May 2022: BeiGene is a worldwide science-driven biotechnology company that focuses on developing innovative and affordable medicines to improve treatment. It outcomes and access for patients worldwide. The company recently announced that the China National Medical Products Administration (NMPA) had granted conditional approval of BLINCYTO® for injection for the treatment of pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia. The NMPA gave conditional approval for adult patients in this indication in December 2020., April 2022: Curis, Inc., a biotechnology company, focuses on developing innovative therapeutics to treat cancer. .

In 2021, the death rate of leukemia among children under 14 years of age in China remained relatively low. Thanks to better healthcare services, Chinese children living in urban regions generally had lower risks of death from leukemia than their counterparts in rural areas. Leukemia is the most common cancer among children and young people in China. With the help of chemotherapy, targeted therapy, and hematopoietic stem cell transplantation, many types of leukemia are now curable.

The T-cell Acute Lymphoblastic Leukemia (T-ALL) treatment market stands at the forefront of cancer therapy innovation, reflecting significant advancements in our understanding and treatment of this aggressive form of leukemia. T-ALL primarily affects children and young adults, requiring effective and specialized int

Deaths from leukaemia. Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07 Type of data: Administrative data

The Acute Myeloid Leukemia (AML) treatment market is a rapidly evolving sector within the healthcare industry, focusing on the management and treatment of this aggressive form of blood cancer. AML, characterized by the rapid proliferation of abnormal myeloid cells, affects thousands of patients worldwide, prompting

According to cognitive market research, the global Chronic Lymphocytic Leukemia Therapeutics market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.

Chronic Lymphocytic Leukemia (CLL) is a type of hematological malignancy marked by excessive proliferation of abnormal white blood cells. CLL predominantly affects the B-cell lymphocytes which are involved in the production of antibodies to fight against infections and foreign antigens. 
One of the main factors propelling the global market is the rising incidence of leukemia worldwide, which is expected to raise demand for leukemia therapeutics.
Even though leukemia treatment, including that for chronic lymphocytic leukemia, is evolving quickly, there aren't many treatment options available for this rare disease. Furthermore, chemotherapy is the mainstay of treatment for chronic lymphocytic leukemia.
Over the course of the forecast period, North America is expected to grow and dominate the market.
The market is propelled by developments in cancer research, which result in the creation of novel treatments and personalized medicine strategies.

Market Dynamics of the Chronic Lymphocytic Leukemia Therapeutics Market

Key Drivers of the Chronic Lymphocytic Leukemia Therapeutics Market

The increasing prevalence of leukemia across the globe drives the market

One of the main factors propelling the global market is the rising incidence of leukemia worldwide, which is expected to raise demand for leukemia therapeutics. Nearly all forms of leukemia, including CML and ALL, are becoming more significant on a global scale. Treatments for CLL include stem cell transplants, chemotherapy, and radiation therapy. CLL treatment is critical as it may help improve symptoms and increase life expectancy. The increasing incidence of chronic lymphocytic leukemia (CLL) can be linked to several factors, including aging populations, environmental influences, and genetic predisposition. With a growing number of CLL patients, there is a rising demand for advanced and targeted therapies that can effectively manage the disease. As the number of CLL patients rises, so does the need for more sophisticated, targeted treatments that can effectively control the illness. • For instance, CLL accounts for about one-quarter of the new cases of leukemia. CLL is the most prevalent adult lymphoid malignancy in the United States. National Cancer Institute estimates the number of new cases of chronic lymphocytic leukemia was 4.7 per 100,000 men and women per year. Men have a slightly higher risk of getting CLL than women. (Source:https://www.cancer.org/cancer/types/chronic-lymphocytic-leukemia/about/key-statistics.html)

Increasing FDA approvals for treating Chronic Lymphocytic Leukemia is expected to drive market growth.

On April 21, 2020, the Food and Drug Administration (FDA) of the United States approved Imbruvica (ibrutinib) in combination with rituximab for the treatment of patients with small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) who had not received prior treatment. Since its approval in 2013, this is the eleventh FDA approval for Imbruvica (ibrutinib), and the sixth for CLL, the most prevalent type of adult leukemia. An increase in the approvals from regulatory bodies and ongoing research activities by the major companies in the United States are likely to contribute the largest share of revenue in the region, propelling the global chronic lymphocytic leukemia market. • For instance, in August 2022, AstraZeneca received the Food and Drug Administration approval for a tablet version of a drug called Calquence for the treatment of Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and previously treated relapsed or refractory Mantle Cell Lymphoma (MCL). (Source:https://www.astrazeneca.com/media-centre/press-releases/2023/calquence-tablet-formulation-approved-in-the-eu-for-patients-with-chronic-lymphocytic-leukaemia.html)

• For instance, AbbVie Inc. received FDA approval for Venclexta in combined application with Gazyva for chronic lymphocytic leukemia treatment. (Source:https://news.abbvie.com/2019-05-15-AbbVie-Announces-US-FDA-Approval-of-VENCLEXTA-R-venetoclax-as-a-Chemotherapy-Free-Combination-Regimen-for-Previously-Untreated-Chronic-Lymphocyti...

BackgroundT-cell suppression in patients with Acute myeloid leukemia (AML) limits tumor cell clearance. This study aimed to explore the role of T-cell senescence-related genes in AML progression using single-cell RNA sequencing (scRNA-seq), bulk RNA sequencing (RNA-seq), and survival data of patients with AML in the TCGA database.MethodsThe Uniform Manifold Approximation and Projection (UMAP) algorithm was used to identify different cell clusters in the GSE116256, and differentially expressed genes (DEGs) in T-cells were identified using the FindAllMarkers analysis. GSE114868 was used to identify DEGs in AML and control samples. Both were crossed with the CellAge database to identify aging-related genes. Univariate and multivariate regression analyses were performed to screen prognostic genes using the AML Cohort in The Cancer Genome Atlas (TCGA) Database (TCGA-LAML), and risk models were constructed to identify high-risk and low-risk patients. Line graphs showing the survival of patients with AML were created based on the independent prognostic factors, and Receiver Operating Characteristic Curve (ROC) curves were used to calculate the predictive accuracy of the line graph. GSE71014 was used to validate the prognostic ability of the risk score model. Tumor immune infiltration analysis was used to compare differences in tumor immune microenvironments between high- and low-risk AML groups. Finally, the expression levels of prognostic genes were verified using polymerase chain reaction (RT-qPCR).Results31 AMLDEGs associated with aging identified 4 prognostic genes (CALR, CDK6, HOXA9, and PARP1) by univariate, multivariate, and stepwise regression analyses with risk modeling The ROC curves suggested that the line graph based on the independent prognostic factors accurately predicted the 1-, 3-, and 5-year survival of patients with AML. Tumor immune infiltration analyses suggested significant differences in the tumor immune microenvironment between low- and high-risk groups. Prognostic genes showed strong binding activity to target drugs (IGF1R and ABT737). RT-qPCR verified that prognostic gene expression was consistent with the data prediction results.ConclusionCALR, CDK6, HOXA9, and PARP1 predicted disease progression and prognosis in patients with AML. Based on these, we developed and validated a new AML risk model with great potential for predicting patients’ prognosis and survival.

The global acute myeloid leukemia therapeutics market size reached USD 1,343.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,461.4 Million by 2033, exhibiting a growth rate (CAGR) of 10.53% during 2025-2033.

IMARC Group provides an analysis of the key trends in each segment of the global acute myeloid leukemia therapeutics market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on treatment type, drug type and route of administration.

Numerous studies have been performed over the last decade to exploit the complexity of genomic and transcriptomic lesions driving the initiation of acute myeloid leukemia (AML). These studies have helped improve risk classification and treatment options. Detailed molecular characterization of longitudinal AML samples is sparse, however; meanwhile, relapse and therapy resistance represent the main challenges in AML care. To this end, we performed transcriptome-wide RNA sequencing of longitudinal diagnosis, relapse, and/or primary resistant samples from 47 adult and 23 pediatric AML patients with known mutational background.

Data consists of a supplemental Pdf file and an Excel file with following tables:

Supplemental Table 1. Study cohort sample overview Supplemental Table 2. Study cohort sample characteristics Supplemental Table 3. Clinical information Supplemental Table 4. Characteristics of CD34+ BM-control samples Supplemental Table 5. Antibody information Supplemental Table 6. RNA-seq statistics Supplemental Table 7. SNVs and small InDels detected by RNA-seq Supplemental Table 8. Comprised metadata and RNA-seq- and WGS/WES results Supplemental Table 9. Fusion transcripts in R/PR AML Supplemental Table 10. Sample usage for generation of various analyses Supplemental Table 11. DEGs associated with short vs. long EFS Supplemental Table 12. GO-analysis of DEGs between short vs. long EFS-associated samples Supplemental Table 13. Statistics associated with survival analyses Supplemental Table 14. DEGs between patient-matched diagnosis and relapse samples Supplemental Table 15. GO-analysis of DEGs between patient-matched diagnosis and relapse samples Supplemental Table 16. Machine learning model rules for diagnosis and relapse in adult AML Supplemental Table 17. Machine learning model rules for diagnosis and relapse in pediatric AML Supplemental Table 18. Machine learning model rules for diagnosis and relapse in pediatric AML (features merged with TARGET) Supplemental Table 19. Machine learning model rules for diagnosis and relapse in the TARGET cohort (features merged with Local Pediatric) Supplemental Table 20. Verification of transcriptomic fusion events and associated primer information

The dataset was originally published in DiVA and moved to SND in 2024.

The Acute Lymphocytic & Lymphoblastic Leukemia (ALL) treatment market represents a crucial segment within the broader oncology landscape, focusing on therapies aimed at addressing one of the most aggressive types of blood cancer, predominantly affecting children and younger adults. This market has grown significantl

For current version see: https://data.sandiegocounty.gov/Health/2021-Non-Communicable-Chronic-Diseases/v7dt-rwpx

Basic Metadata *Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

***API: Asian/Pacific Islander. ***AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Code Source: ICD-9CM - AHRQ HCUP CCS v2015. ICD-10CM - AHRQ HCUP CCS v2018. ICD-10 Mortality - California Department of Public Health, Group Cause of Death Codes 2013; NHCS ICD-10 2e-v1 2017.

Data Guide, Dictionary, and Codebook: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20Codebook_Data%20Guide_Metadata_10.2.19.xlsx